Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
View Older Stories
-
TD Cowen Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
-
Syndax Announces Participation at Two Upcoming Investor Conferences
-
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
-
Syndax Pharmaceuticals (SNDX) Prices 10.81M Share Offering at $18.50/sh
-
Syndax Announces Pricing of $200 Million Public Offering of Common Stock
-
Syndax Pharmaceuticals (SNDX) Announces Proposed $150M Share Offering
-
Syndax Announces Proposed $150 Million Public Offering of Common Stock
-
Syndax Announces Participation at Two Upcoming Investor Conferences
-
Syndax Announces Participation at Upcoming Investor Conferences
-
Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Syndax Pharmaceuticals (SNDX) Prices 6.82M Share Offering at $22
-
Syndax Announces Pricing of $150 Million Public Offering of Common Stock
-
Syndax Pharmaceuticals (SNDX) Announces Proposed $150 million Public Offering of Common Stock
-
Syndax Announces Proposed $150 million Public Offering of Common Stock
-
Syndax Announces Participation at Two Upcoming Investor Conferences
-
Syndax Announces Participation at Two Upcoming Investor Conferences
-
Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
-
Syndax Pharmaceuticals (SNDX) Prices 4.3M Share and Warrant Offering at $17.50/sh
-
Syndax Announces Pricing of $75.3 Million Public Offering
-
Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit
-
Syndax Announces Participation at Two Upcoming Investor Conferences
-
Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
-
Syndax Pharmaceuticals (SNDX) Prices 5.43M Share Public Offering of Common Stock at $23/sh
-
Syndax Announces Pricing of Public Offering of Common Stock
-
Syndax Pharmaceuticals (SNDX) Announces Proposed Public Offering of Common Stock
-
Syndax Announces Proposed Public Offering of Common Stock
-
Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Syndax Pharmaceuticals (SNDX) Prices 5.56M Common Stock Offering at $18/sh
-
Syndax Announces Pricing of Public Offering of Common Stock
-
Syndax Pharmaceuticals (SNDX) Announces Proposed Public Offering of Common Stock
-
Syndax Announces Proposed Public Offering of Common Stock
-
Syndax Announces Participation at Two Upcoming Investor Conferences
-
Syndax to Present at the Cowen 39th Annual Health Care Conference
-
Pre-Open Movers 09/25: (ASNA) (TLRY) (NIHD) Higher; (TGTX) (OPNT) (SNDX) Lower (more...)
-
Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
-
Syndax Pharmaceuticals (SNDX) Prices 3.75M Share Offering at $13.25/Sh
-
Syndax Prices Public Offering of Common Stock
-
Syndax Pharmaceuticals (SNDX) Announces $50M Offering of Common Stock
-
Syndax Announces Proposed Public Offering of Common Stock
-
Syndax (SNDX) Entinostat+Keytruda Combo Data 'Unexpected and Impressive' - Cowen
-
Cowen Starts Syndax Pharmaceuticals (SNDX) at Outperform
-
Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

